Treatment Outcomes After 3 Years in Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen
Author:
Funder
Genentech
Publisher
Elsevier BV
Subject
Ophthalmology
Reference19 articles.
1. Ranibizumab for neovascular age-related macular degeneration;Rosenfeld;N Engl J Med,2006
2. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;N Engl J Med,2006
3. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results;Martin;Ophthalmology,2012
4. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial;Chakravarthy;Lancet,2013
5. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study;Schmidt-Erfurth;Ophthalmology,2011
Cited by 101 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Assistance Burden Comparison Between Age-Related Macular Degeneration and Retinal Angiomatous Proliferation Over a Three-Year Follow-up;Ophthalmic Surgery, Lasers and Imaging Retina;2024-04
2. STRICT PRO RE NATA VERSUS TREAT-AND-EXTEND REGIMENS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION;Retina;2023-03
3. MALDI and Trace Metal Analysis in Age-Related Macular Degeneration;Methods in Molecular Biology;2023
4. Impact of Treating Age-Related Macular Degeneration before Visual Function Is Impaired;Journal of Clinical Medicine;2022-09-27
5. Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission;Scientific Reports;2022-09-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3